Jove
Visualize
Contact Us

Related Experiment Videos

Renin inhibitors.

W J Greenlee1

  • 1Merck Sharp and Dohme Research Laboratories, Merck and Co., Inc., Rahway, New Jersey 07065.

Pharmaceutical Research
|October 1, 1987
PubMed
Summary

Renin inhibitors offer a targeted approach to managing hypertension and heart failure, presenting potential advantages over current treatments. Recent advancements are bringing these potent, low molecular weight agents closer to clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The chemistry of drug design and lead optimization. Editorial overview.

Current opinion in drug discovery & development·2009
Same author

The chemistry of drug design and lead optimization. Editorial overview.

Current opinion in drug discovery & development·2009
Same author

Editorial overview. The chemistry of drug design and lead optimization.

Current opinion in drug discovery & development·2009
Same author

Tetrahydroisoquinolines as MCH-R1 antagonists.

Bioorganic & medicinal chemistry letters·2006
Same author

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.

Journal of medicinal chemistry·2001
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Management
  • Drug Development

Background:

  • Pharmacological intervention in the renin-angiotensin system (RAS) is crucial for treating hypertension and heart failure.
  • Angiotensin-converting enzyme (ACE) inhibitors are effective but target a later step in the RAS.
  • The success of ACE inhibitors has spurred interest in targeting renin, the rate-limiting enzyme in the RAS.

Purpose of the Study:

  • To review recent advances in the development of renin inhibitors.
  • To highlight progress toward clinically useful renin inhibitors.
  • To discuss the potential advantages of renin inhibition over less specific antihypertensive agents.

Main Methods:

  • Review of scientific literature on renin inhibitor development.
  • Analysis of progress in creating potent, low molecular weight renin inhibitors.
  • Evaluation of the specificity and therapeutic potential of renin inhibitors.

Main Results:

  • Substantial progress has been made in developing potent, low molecular weight renin inhibitors.
  • Renin inhibitors offer high specificity for their endogenous substrate.
  • These inhibitors show promise as therapeutic agents for hypertension and heart failure.

Conclusions:

  • Renin inhibitors represent a promising therapeutic strategy with potential advantages due to their specific mode of action.
  • Recent developments indicate that clinically useful renin inhibitors are becoming a reality.
  • Targeting renin offers a novel approach to managing cardiovascular diseases.

Related Experiment Videos